%0 Journal Article
%T First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
%A Caicun Zhou
%A Hui Liu
%A Qinghua Xu
%A Shengxiang Ren
%A Shixiong Liang
%A Shuyan Meng
%A Tao Jiang
%A Xuefei Li
%J Journal of Cancer
%D 2019
%I Ivyspring International Publisher
%R 10.7150/jca.26494
%X Introduction: The effect of local ablative therapy (LAT) for oligoprogressive epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) remains undetermined. This study aimed to investigate the survival benefit of addition of LAT to EGFR-TKIs in EGFR-mutant NSCLC patients with oligoprogression during TKI therapy.
%U http://www.jcancer.org/v10p0522.htm